Analysts Offer Insights on Healthcare Companies: Arena Pharma (NASDAQ: ARNA) and Endo International (NASDAQ: ENDP)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arena Pharma (NASDAQ: ARNA) and Endo International (NASDAQ: ENDP).

Arena Pharma (NASDAQ: ARNA)

In a report issued on March 15, Rahul Jasuja from FBR Capital reiterated a Buy rating on Arena Pharma (NASDAQ: ARNA), with a price target of $6. The company’s shares closed yesterday at $1.57.

According to TipRanks.com, Jasuja is ranked 0 out of 5 stars with an average return of -9.6% and a 36.4% success rate. Jasuja covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Asterias Biotherapeutics, and Palatin Technologies.

Arena Pharma has an analyst consensus of Moderate Buy.

Endo International (NASDAQ: ENDP)

William Blair analyst Tim Lugo reiterated a Hold rating on Endo International (NASDAQ: ENDP) on March 15. The company’s shares closed yesterday at $10.66, close to its 52-week low of $9.82.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 15.6% and a 36.8% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, CoLucid Pharmaceuticals, and Adverum Biotechnologies.

Currently, the analyst consensus on Endo International is Hold and the average price target is $17.33, representing a 62.6% upside.

In a report issued on February 28, Canaccord Genuity also reiterated a Hold rating on the stock with a $14 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.